Dr. Bernard Verbeeten Instituut Stichting
- Address
- lock Available on a paid plan
Digestive System Oncology
At Dr. Bernard Verbeeten Instituut Stichting in Tilburg, clinical research in Radiation Oncology focuses on digestive system diseases and neoplasms, especially cancers of the rectum and esophagus. These studies are designed to improve treatment choices, support organ preservation, and strengthen cancer control for patients with complex gastrointestinal tumors.
- Locally recurrent rectal cancer and rectal cancer
- Early-stage rectal cancer and intermediate-risk early rectal cancer
- HER2 positive esophageal adenocarcinoma
The research includes comparisons of treatment approaches to improve surgical outcomes, assess oncological safety, and test whether adding new therapies can enhance survival and disease control.
Rectal Cancer Treatment and Organ Preservation
Several trials at this site examine ways to treat rectal cancer while preserving the rectum whenever safely possible. The work centers on balancing effective cancer treatment with better long-term quality of life, including studies of local treatment strategies and follow-up approaches after initial therapy.
- Organ preservation in early-stage rectal cancer
- Safety of rectal-preserving therapy
- Clear resection margins after treatment
These studies aim to determine which patients can avoid more extensive surgery without compromising cancer outcomes.
Esophageal Cancer Research
Research on HER2 positive esophageal adenocarcinoma is evaluating whether adding targeted therapies can improve the effectiveness of standard cancer treatment. This line of work is part of a broader effort to refine care for patients with resectable upper digestive tract tumors.
- HER2-targeted treatment in esophageal adenocarcinoma
- Improving survival in resectable esophageal cancer
- Enhancing response to standard therapy
The main purpose is to test whether targeted treatment combinations can lead to better outcomes than standard care alone.
Prostate Cancer and Metastatic Disease
The site also studies prostate cancer in patients with biochemical recurrence and limited metastatic spread. This research explores how metastasis-directed radiotherapy and hormonal treatment may help delay progression and improve disease control in carefully selected patients.
- Biochemical recurrence after primary prostate cancer treatment
- Oligometastatic prostate cancer
- Combining radiotherapy with hormonal support
The goal is to evaluate whether treatment intensification can prolong the time before the disease worsens.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Amsterdam UMC Stichting2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amsterdam UMC Stichting3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr. Bernard Verbeeten Instituut Stichting
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Bintrafusp Alfa Combined with Chemoradiation in Esophageal Squamous Cell Carcinoma: A Feasibility Study | Amsterdam UMC Stichting | Phase II | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 4 | Unknown | 2017-10-09 | 2025-01-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.